Chronic lung allograft dysfunction (CLAD) is the leading cause of long-term mortality after lung transplantation. Several risk factors for CLAD have been identified, but the exact pathophysiology and triggering molecular factors remain largely unknown. Moreover, in clinical practice, no integration of the different risk factors is achieved. CLAD is therefore diagnosed most often late with the persistent decline in respiratory function, revealing a profound and irreversible alteration of the pulmonary graft. Several blood biomarkers that can predict the occurrence of CLAD more than 6 months before clinical diagnosis have been identified and validated. From these preliminary results, a composite score is being developed from independent samples from the COLT (COhort in Lung Transplantation) cohort. The main objective of this project is to validate this robust and predictive composite score (biological and clinical) of CLAD.
Study Type
OBSERVATIONAL
Enrollment
240
CHU de Bordeaux
Bordeaux, France
CHU de Grenoble
Grenoble, France
Centre Chirurgical Marie Lannelongue
Le Plessis-Robinson, France
CHU de Lyon
Lyon, France
AP-HM
Marseille, France
CHU de Nantes
Nantes, France
Hôpital Bichat
Paris, France
CHRU de Strasbourg
Strasbourg, France
Hôpital Foch
Suresnes, France
CHU de Toulouse
Toulouse, France
MMP-9 levels in plasma, gene expression and lymphocyte levels in blood associated with Chronic Lung Allograft Dysfunction (CLAD)
Time frame: 3 years
Expression of the 3 genes BLK, POU2AF1 and TCL1A in whole blood associated with CLAD
Time frame: 3 years
MMP-9 levels over time associated with CLAD
Time frame: 3 years
Transitional B lymphocytes rate over time associated with CLAD
Time frame: 3 years
T lymphocytes levels over time associated with CLAD
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.